• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training

Idiopathic pulmonary fibrosis Pipeline Dashboard, H1 2018

Scope of report

  • The report provides a snapshot of the global therapeutic landscape of Idiopathic pulmonary fibrosis.
  • The report assesses Idiopathic pulmonary fibrosis pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • The report reviews Idiopathic pulmonary fibrosis pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development for Idiopathic pulmonary fibrosis ranging from discovery to pre-registration and undisclosed stages.

Companies Covered:

DS Biopharma, Boehringer Ingelheim, Samumed, MSM Protein Technologies, Ribomic, FibroStatin, StemMed, HEC Pharm, mondoBIOTECH, Nuevolution, Chiesi, Glenmark Pharmaceuticals Ltd, Respira Therapeutics, NuMedii, Abeome Corporation, Proterris, RespiVert, Asahi Kasei Pharma Corp

Key Drugs:

Pirfenidone, Pamrevlumab, AEOL 10150, Sonolisib, Nintedanib, Tipelukast, Lebrikizumab, STX 100, Carlumab, Dectrekumab, Tanzisertib, PBI 4050, PRM 151, Omipalisib, BMS 986020, SAR 156597, Collagen type V oral solution, Acetylcysteine/pentoxifylline, KD 025

Publisher: Pharmintel

Format: Microsoft Excel
Sheets: 8

  • Single Use:  $300
  • Site License: $500
  • Global License: $800

Report Inquiry

Leave a Reply

Your email address will not be published. Required fields are marked *

+91 9643310025, 9643312749
© 2024 Pharmintel